company background image
CZO

Ceapro TSXV:CZO Stock Report

Last Price

CA$0.67

Market Cap

CA$52.4m

7D

3.1%

1Y

3.1%

Updated

30 Sep, 2022

Data

Company Financials
CZO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

CZO Stock Overview

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally.

Ceapro Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ceapro
Historical stock prices
Current Share PriceCA$0.67
52 Week HighCA$0.82
52 Week LowCA$0.40
Beta1.36
1 Month Change-15.19%
3 Month Change13.56%
1 Year Change3.08%
3 Year Change71.80%
5 Year Change-4.29%
Change since IPO-62.78%

Recent News & Updates

Jun 17
Ceapro's (CVE:CZO) Returns Have Hit A Wall

Ceapro's (CVE:CZO) Returns Have Hit A Wall

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...

Shareholder Returns

CZOCA ChemicalsCA Market
7D3.1%-3.4%-2.9%
1Y3.1%26.0%-6.2%

Return vs Industry: CZO underperformed the Canadian Chemicals industry which returned 26% over the past year.

Return vs Market: CZO exceeded the Canadian Market which returned -6.2% over the past year.

Price Volatility

Is CZO's price volatile compared to industry and market?
CZO volatility
CZO Average Weekly Movement8.2%
Chemicals Industry Average Movement11.3%
Market Average Movement9.9%
10% most volatile stocks in CA Market18.1%
10% least volatile stocks in CA Market3.8%

Stable Share Price: CZO is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CZO's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997n/aGilles Gagnonhttps://www.ceapro.com

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. It operates in two segments, Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment develops proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries.

Ceapro Fundamentals Summary

How do Ceapro's earnings and revenue compare to its market cap?
CZO fundamental statistics
Market CapCA$52.41m
Earnings (TTM)CA$5.31m
Revenue (TTM)CA$19.76m

9.9x

P/E Ratio

2.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CZO income statement (TTM)
RevenueCA$19.76m
Cost of RevenueCA$7.37m
Gross ProfitCA$12.39m
Other ExpensesCA$7.08m
EarningsCA$5.31m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.068
Gross Margin62.70%
Net Profit Margin26.88%
Debt/Equity Ratio0%

How did CZO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CZO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CZO?

Other financial metrics that can be useful for relative valuation.

CZO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA6.2x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does CZO's PE Ratio compare to its peers?

CZO PE Ratio vs Peers
The above table shows the PE ratio for CZO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average12.9x
NEO Neo Performance Materials
6.5x-7.4%CA$460.5m
WRX Western Resources
55.4xn/aCA$99.9m
MJS Majestic Gold
4.8xn/aCA$52.1m
SGI Superior Gold
7.3xn/aCA$46.8m
CZO Ceapro
9.9xn/aCA$52.4m

Price-To-Earnings vs Peers: CZO is good value based on its Price-To-Earnings Ratio (9.9x) compared to the peer average (12.9x).


Price to Earnings Ratio vs Industry

How does CZO's PE Ratio compare vs other companies in the North American Chemicals Industry?

Price-To-Earnings vs Industry: CZO is good value based on its Price-To-Earnings Ratio (9.9x) compared to the North American Chemicals industry average (10.8x)


Price to Earnings Ratio vs Fair Ratio

What is CZO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CZO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CZO's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of CZO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CZO (CA$0.67) is trading below our estimate of fair value (CA$1.92)

Significantly Below Fair Value: CZO is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Ceapro forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-16.4%

Forecasted Materials industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ceapro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Ceapro is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Ceapro competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Ceapro performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


56.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CZO has high quality earnings.

Growing Profit Margin: CZO's current net profit margins (26.9%) are higher than last year (5.5%).


Past Earnings Growth Analysis

Earnings Trend: CZO's earnings have grown significantly by 56% per year over the past 5 years.

Accelerating Growth: CZO's earnings growth over the past year (528.8%) exceeds its 5-year average (56% per year).

Earnings vs Industry: CZO earnings growth over the past year (528.8%) exceeded the Chemicals industry 278.8%.


Return on Equity

High ROE: CZO's Return on Equity (17.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Ceapro's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CZO's short term assets (CA$17.1M) exceed its short term liabilities (CA$917.1K).

Long Term Liabilities: CZO's short term assets (CA$17.1M) exceed its long term liabilities (CA$2.9M).


Debt to Equity History and Analysis

Debt Level: CZO is debt free.

Reducing Debt: CZO has no debt compared to 5 years ago when its debt to equity ratio was 8.8%.

Debt Coverage: CZO has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CZO has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Ceapro current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Ceapro Dividend Yield vs Market
How does Ceapro dividend yield compare to the market?
SegmentDividend Yield
Company (Ceapro)n/a
Market Bottom 25% (CA)2.0%
Market Top 25% (CA)6.1%
Industry Average (Chemicals)2.4%
Analyst forecast in 3 Years (Ceapro)n/a

Notable Dividend: Unable to evaluate CZO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CZO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CZO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CZO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CZO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Gilles Gagnon (68 yo)

15yrs

Tenure

CA$560,000

Compensation

Mr. Gilles R. Gagnon, M.Sc., MBA, ICD D, serves as Director at Aeterna Zentaris Inc. since January 1, 2020. He serves as the President of Spectrum Pharma Canada Inc. (Spectrum Canada).Mr. Gagnon has been...


CEO Compensation Analysis

Gilles Gagnon's Compensation vs Ceapro Earnings
How has Gilles Gagnon's remuneration changed compared to Ceapro's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

CA$5m

Mar 31 2022n/an/a

CA$4m

Dec 31 2021CA$560kCA$480k

CA$3m

Sep 30 2021n/an/a

CA$2m

Jun 30 2021n/an/a

CA$844k

Mar 31 2021n/an/a

CA$1m

Dec 31 2020CA$507kCA$480k

CA$2m

Sep 30 2020n/an/a

CA$3m

Jun 30 2020n/an/a

CA$2m

Mar 31 2020n/an/a

CA$630k

Dec 31 2019CA$518kCA$480k

-CA$1m

Sep 30 2019n/an/a

-CA$855k

Jun 30 2019n/an/a

-CA$1m

Mar 31 2019n/an/a

-CA$657k

Dec 31 2018CA$555kCA$480k

-CA$316k

Sep 30 2018n/an/a

-CA$2m

Jun 30 2018n/an/a

-CA$2m

Mar 31 2018n/an/a

-CA$1m

Dec 31 2017CA$1mCA$480k

-CA$958k

Sep 30 2017n/an/a

CA$809k

Jun 30 2017n/an/a

CA$1m

Mar 31 2017n/an/a

CA$2m

Dec 31 2016CA$402kCA$252k

CA$4m

Sep 30 2016n/an/a

CA$7m

Jun 30 2016n/an/a

CA$7m

Mar 31 2016n/an/a

CA$6m

Dec 31 2015CA$377kCA$252k

CA$5m

Compensation vs Market: Gilles's total compensation ($USD407.88K) is above average for companies of similar size in the Canadian market ($USD176.56K).

Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CZO's management team is seasoned and experienced (7.3 years average tenure).


Board Members

Experienced Board: CZO's board of directors are considered experienced (7.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of CZO?
Owner TypeNumber of SharesOwnership Percentage
Private Companies250,0000.3%
Individual Insiders2,815,5423.6%
General Public75,152,63596.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 5 shareholders own 3.92% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
1.9%
Gilles Gagnon
1,489,000CA$997.6k11.2%no data
1.47%
Glenn Rourke
1,146,636CA$768.2k0%no data
0.32%
Prodev Pharma Inc
250,000CA$167.5k0%no data
0.13%
William Li
101,579CA$68.1k0%no data
0.1%
Ulrich Kosciessa
78,327CA$52.5k0%no data

Company Information

Ceapro Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Ceapro Inc.
  • Ticker: CZO
  • Exchange: TSXV
  • Founded: 1997
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Implied Market Cap: CA$52.406m
  • Shares outstanding: 78.22m
  • Website: https://www.ceapro.com

Location

  • Ceapro Inc.
  • 7824 – 51 Avenue NW
  • Edmonton
  • Alberta
  • T6E 6W2
  • Canada


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CZOTSXV (TSX Venture Exchange)YesClass A Voting Common SharesCACADSep 1988
CRPO.FOTCPK (Pink Sheets LLC)YesClass A Voting Common SharesUSUSDSep 1988

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/29 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.